People · Operator
Named in public records as an officer, director or promoter · active 2010–2014 · Biotechnology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Tolera Therapeutics Inc | — | Biotechnology | Series A | $13.9M | $9.0M | 2010 |
| Cour Pharmaceuticals Development Co Inc | — | Biotechnology | Pre-Seed | $669K | $9.3M | 2014 |
John Puisis at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside John Puisis on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Donald Parfet | 1 | 5 |
| Mark Olesnavage | 1 | 4 |
| Ashleigh Palmer | 1 | 4 |
| Suzette Dutch | 1 | 3 |
| Douglas Morton | 1 | 3 |
| Catherine J. Mackey | 1 | 2 |
| James Herrmann | 1 | 1 |
| Daniel Getts | 1 | 1 |
| John J. Puisis | 1 | 1 |
| James J. Herrmann | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.